Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives ...
It was later discovered that one of the donors was HIV positive, leading to her infection..HIV, AIDS, Cancer patient, RCC, Kerala High Court ...
Providing feedback following point-of-care urine testing for tenofovir concentrations was associated with increased PrEP ...
HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...
Newspoint on MSN23h
Get one injection in a year and get rid of the tension of HIV! It can be a boon for such peopleScientists have got success with a new injection of HIV. Taking this injection once a year can reduce the risk of HIV ...
Verywell Health on MSN20h
Bacterial Vaginosis May Be Sexually Transmitted, New Study SuggestsA new study in Australia found that treating male partners can reduce BV reinfections, suggesting that BV may be sexually ...
Prof. Francisca Mutapi, a global health expert suggests 4 ways to end the dependence HEALTH | FRANCISCA MUTAPI | There’s been a global trend in the reduction of aid to Africa since 2018. Donors are ...
A bill to ensure NH’s Medicaid program doesn’t pay for circumcisions unless medically necessary was approved by the House by ...
Presented promising PK, pharmacodynamic, and safety results for Decoy20 at the American Society for Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC) annual meetings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback